<DOC>
	<DOCNO>NCT01942070</DOCNO>
	<brief_summary>The aim current study test clinical performance everolimus-eluting BVS compare durable polymer everolimus-eluting stent ( EES ) patient undergo PCI set acute MI .</brief_summary>
	<brief_title>A Prospective , Randomized Trial BVS Veruss EES Patients Undergoing Coronary Stenting Myocardial Infarction</brief_title>
	<detailed_description>Percutaneous coronary intervention ( PCI ) drug-eluting stent ( DES ) implantation currently represent dominant treatment strategy patient undergoing catheter intervention . However effective neointimal suppression occur cost systematic delay arterial heal comparison bare metal stenting . This underlie small significant increase risk stent thrombosis DES implantation comparison bare metal stent implantation well possible excess in-stent neoatheroma formation . Bioresorbable vascular scaffold ( BVS ) represent innovative technology provide short-term vessel scaffold drug delivery without long-term limitation metallic DES durable polymer coating . Potential benefit include restoration normal vasomotor reactivity , facilitation positive vessel wall remodelling facilitation subsequent bypass grafting stented arterial segment . In addition preliminary report suggest process scaffold biodegradation may promote formation cohesive tissue layer cover stabilize underlying atherosclerotic plaque - so-called plaque-sealing effect . Although initial result BVS encouraging , lack randomize clinical trial data data exists outcomes BVS implantation patient undergoing coronary stenting set acute myocardial infarction ( MI ) . The aim current study test clinical performance everolimus-eluting BVS compare durable polymer everolimus-eluting stent ( EES ) patient undergo PCI set acute MI . The primary endpoint percentage diameter stenosis protocol-mandated 6-8 month angiographic follow-up . Sample size calculation base non-inferiority assumption relation BVS versus EES . It plan enrol total 260 patient . Subsequent clinical follow-up undertaken 5 year .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Patients 18 year old acute STelevation myocardial infarction non STelevation myocardial infarction angiographically confirm thrombus 2 . Planned stent implantation de novo lesion native vessel coronary bypass graft reference vessel diameter ≥2.5 mm ≤3.9 mm 3 . Written , inform consent patient her/his legallyauthorized representative participation study 4 . In woman childbearing potential negative pregnancy test mandatory 1 . Target lesion locate leave main trunk 2 . Severely calcified lesion 3 . Bifurcation lesion side branch diameter &gt; 2mm 4 . Instent restenosis 5 . Contraindications antiplatelet therapy , cobalt chrome , everolimus , polylactic acid 6 . Malignancies comorbid condition ( example severe liver , renal pancreatic disease ) life expectancy le 12 month may result protocol noncompliance 7 . Pregnancy ( present , suspected plan ) positive pregnancy test . 8 . Previous enrolment trial 9 . Patient 's inability fully cooperate study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Cardiovascular Disease</keyword>
	<keyword>Myocardial Infarction</keyword>
	<keyword>Bioresorbable vascular scaffold</keyword>
	<keyword>Durable polymer everolimus-eluting stent</keyword>
	<keyword>Primary angioplasty</keyword>
	<keyword>Stent</keyword>
</DOC>